LeonaBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
LeonaBio, Inc. (LONA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 2.09 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-14
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 2.09K shares, a 99.67% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 8.08K shares, a 99.62% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was -1.99M shares.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 246.81K shares, a 88.71% decline from fiscal 2024.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 2.19M shares, a 179.90% increase from fiscal 2023.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 780.90K shares, a 367.23% increase from fiscal 2022.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 167.13K shares, a 64.08% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 2.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 2.09K shares 10-Q · filed 2026-08-14 | 10.17K shares derived: sum of 3 quarters · filed 2026-08-14 | -1.98M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | 8.08K shares derived: sum of 2 quarters · filed 2026-05-07 | -1.98M shares derived: sum of 3 quarters · filed 2026-05-07 | -1.35M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 8.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -1.98M shares derived: sum of 2 quarters · filed 2026-03-31 | -1.35M shares derived: sum of 3 quarters · filed 2026-03-31 | 246.81K shares 10-K · filed 2026-03-31 |
| 2025-09-30 | -1.99M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -1.36M shares derived: sum of 2 quarters · filed 2025-11-06 | 238.74K shares 10-Q · filed 2025-11-06 | 2.37M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 629.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.23M shares 10-Q · filed 2025-08-07 | 4.36M shares derived: sum of 3 quarters · filed 2025-08-07 | 4.36M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.60M shares 10-Q · filed 2025-05-09 | 3.73M shares derived: sum of 2 quarters · filed 2025-05-09 | 3.73M shares derived: sum of 3 quarters · filed 2025-05-09 | 3.75M shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 2.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 2.14M shares derived: sum of 2 quarters · filed 2025-02-27 | 2.15M shares derived: sum of 3 quarters · filed 2025-02-27 | 2.19M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 11.35K shares derived: sum of 2 quarters · filed 2024-11-07 | 50.57K shares 10-Q · filed 2024-11-07 | 201.57K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 11.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 50.57K shares 10-Q · filed 2024-08-01 | 201.57K shares derived: sum of 3 quarters · filed 2024-08-01 | 608.29K shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 39.22K shares 10-Q · filed 2024-05-15 | 190.22K shares derived: sum of 2 quarters · filed 2024-05-15 | 596.94K shares derived: sum of 3 quarters · filed 2024-05-15 | 740.29K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 151.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 557.73K shares derived: sum of 2 quarters · filed 2024-02-22 | 701.07K shares derived: sum of 3 quarters · filed 2024-02-22 | 780.90K shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 406.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 550.07K shares derived: sum of 2 quarters · filed 2023-11-09 | 629.90K shares 10-Q · filed 2023-11-09 | 663.29K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 143.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 223.18K shares 10-Q · filed 2023-08-10 | 256.56K shares derived: sum of 3 quarters · filed 2023-08-10 | 261.08K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 79.83K shares 10-Q · filed 2023-05-11 | 113.22K shares derived: sum of 2 quarters · filed 2023-05-11 | 117.73K shares derived: sum of 3 quarters · filed 2023-05-11 | 136.13K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 33.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 37.90K shares derived: sum of 2 quarters · filed 2023-03-23 | 56.30K shares derived: sum of 3 quarters · filed 2023-03-23 | 167.13K shares 10-K · filed 2023-03-23 |
| 2022-09-30 | 4.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 22.91K shares derived: sum of 2 quarters · filed 2022-11-10 | 133.75K shares 10-Q · filed 2022-11-10 | 535.47K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 18.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 129.23K shares 10-Q · filed 2022-08-15 | 530.96K shares derived: sum of 3 quarters · filed 2022-08-15 | 592.08K shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 110.83K shares 10-Q · filed 2022-05-12 | 512.56K shares derived: sum of 2 quarters · filed 2022-05-12 | 573.68K shares derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | 401.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 462.85K shares derived: sum of 2 quarters · filed 2022-03-28 | 465.25K shares 10-K · filed 2022-03-28 | |
| 2021-09-30 | 61.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 63.52K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 2.40K shares 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | 10.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 52.02K shares 10-K · filed 2021-03-25 | ||
| 2020-09-30 | 41.30K shares 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |